Angiogenesis, the formation of new blood vessels from pre-existing vessels, occurs physiologically during embryonal development, tissue injury and inflammation. It is also well known to play an important role in several pathological conditions, such as cancer, diabetic retinopathy, rheumatoid arthritis and atherosclerosis.
The formation of new capillaries is a complex biological process whose regulatory mechanisms are incompletely understood. The initiation of angiogenesis involves focal reduction of intercellular interactions and of interactions between endothelial cells and the surrounding extracellular matrix (ECM). Cell migration, proliferation and capillary tube formation then follow. It is clear that complex orchestration of many processes, some overlapping, is required in order for angiogenesis to proceed. Various types of angiogenic growth factors such as vascular endothelial growth factor (VEGF), 3) basic fibroblast growth factor (bFGF), 4) platelet-derived growth factor (PDGF) 5) and hepatocyte growth factor (HGF) 6) stimulate both the endothelial cells and mesenchymal cells. ECM-degrading proteolytic enzymes, including matrix metalloprotease (MMP) and plasminogen activator (PA), are secreted by endothelial cells in response to angiogenic factors and/or cytokines. 7) Cell adhesion molecules such as integrins, cadherin and PECAM also regulate the angiogenic process. 8) There are some reports on the interactions of the angiogenic factors mentioned above; for example, bFGF up-regulates VEGF production 9) ; the production of proteolytic enzymes and integrin alpha subunits is induced by VEGF, 10) bFGF 11) and PDGF 12) ; MMP-2 associates with integrin avb3 and growth factor receptor. 13) Therefore, an in vitro model of angiogenesis should retain, as far as possible, the in vivo interactions of angiogenic factors and the regulatory mechanisms.
Fragments of rat thoracic aorta within type I collagen gel provide a good model of the overall angiogenic process, including cell migration, proliferation and capillary tube formation, for 1 to 2 weeks. The aortic fragments contain several types of cells, such as endothelial cells, smooth muscle cells and fibroblasts, which co-ordinate to form capillary vessels in the collagen gel. It was reported that aortic fragments endogenously produce bFGF, 14) and exogenous growth factors such as PDGF, insulin-like growth fator (IGF) and VEGF enhance capillary formation. 15) In this report, we show that VEGF, its receptor and proteolytic enzymes (MMP, PA) are endogenously expressed in the rat aorta model and gradually increase during the process of angiogenesis. When the action of these endogenous factors was blocked by inhibitors, capillary tube formation was clearly inhibited, demonstrating that these endogenous factors play key roles in angiogenesis in this model. Interestingly, the formed capillaries and migrating cells showed different morphologies when different inhibitors (endothelial cell growth inhibitor, MMP inhibitor, dexamethasone and VEGF receptor kinase inhibitor) were used. Our results suggest that the rat aorta model represents an overall in vitro angiogenic process, and can distinguish the characteristics of different angiogenesis inhibitors on a mechanism basis. We further found that luminacin, a natural microbial metabolite identified by us as a novel angiogenesis inhibitor, 16) inhibited the capillary formation and induced a characteristic sheetlike structure in the rat aorta model, suggesting that it has an unique mechanism of inhibition of the angiogenic process.
MATERIALS AND METHODS

Chemicals
Dexamethasone was purchased from SigmaAldrich Japan (Tokyo, Japan). The chemical identity of TNP-470, marimastat and SU5416 was supported by nuclear magnetic resonance and mass spectroscopy data.
Rat Aorta Matrix Culture Rat aorta matrix gels were prepared by the method described previously. 17) Briefly, thoracic aortas were obtained from 8-to 12-week-old male Sprague-Dawley rats. The fibroadipose tissue around the aorta was carefully removed and rinsed with Hank's solution (Gibco BRL, Gaitherburg, U.S.A.). The aortas were cut into small fragments (2ϫ2 mm) and transferred to wells of a 24-well culture plate containing 0.5 ml of type I collagen gel (Nitta Gelatin, Tokyo, Japan). After collagen gelation, 0.5 ml of MCDB 131 medium (Kurorera, Tokyo, Japan) was added on top of the gel in the wells. The medium was changed to inhibitor-containing medium on day 1 and on day 4. At 7 d after the beginning of the experiment (day 7), microvessels were counted and a photograph was taken under a light microscope. Microvascular sprouts were distinguished from fibroblasts or sheet-like structure (greater thickness and uniformly cohesive pattern of growth) and the number of microvascular tips was counted as a tube number. Testing was conducted using four cultures per dose and results were confirmed by repeated experiments. Inhibition rate (%) was determined by the formula below.
inhibition (%)ϭ(mean number of vessels in control wells
Ϫmean number of vessels in treated wells) /(mean number of vessels in control wells)ϫ100 (%)
IC 50 values were generated from separated sigmoidal curves.
Gelatin Zymography Conditioned medium of rat aorta collagen matrix culture was mixed with an equal volume of dye buffer (0.01% BPB, 2% SDS, 30% glycerol, 0.25 M Tris-HCl pH 6.8) and subjected to 10% SDS-PAGE containing 0.1% gelatin. The electrophoresis gel was washed in 2.5% Triton X-100 for 1 h followed by soaking overnight in 50 mM Tris-HCl pH 7.6, 2 mM CaCl 2 . The gel was stained with 0.1% Coomassie brilliant blue solution.
RNA Analysis One piece of aorta fragment on day 0 and on day 7 in matrix culture was dissolved with 100 ml of denaturing solution in Total RNA isolation kit (Clontech Lab. Inc., California, U.S.A.). Ten microliters of 2 M sodium acetate, 100 ml of phenol and 60 ml of CHCl 3 /isoamyl alcohol (49 : 1) were added and vortex for 10 s, followed by standing on ice for 15 min. After centrifuging by 15000 rpm at 4°C for 15 min, 110 ml of aqueous phase were separated and equal volume of isopropanol were added. The solution was chilled at Ϫ70°C, followed by centrifuging by 15000 rpm at 4°C for 15 min. The precipitant was washed with 75% EtOH and dissolved with 10 ml of H 2 O. Two microliters of RNA solution were subjected to a reverse transcriptase-PCR analysis using random hexamers as reverse transcriptase primers. Specific primers for PCR amplification were designed based on the rat cDNA sequence as follows:
TACCTCCACCATGCCAAGTGGT, TATCTTTCTTTG-GTCTGCATTC for rat VEGF, CAGCCTGTCTACATCAT-TATGGAA, TTGTTCCCGTGCTTGCTGGTTT for rat Flk and ATCATGTTTGAGACCTTCAACA, AAGGAAGGCTG-GAAGAGAGCCT for rat b-actin. The PCR was run for 30 cycles and products were analyzed by 1% agarose gel electrophoresis.
Measurement of Plasminogen Activator Aortic fragments were cultured in 24-well plate (4 fragments/well) containing 0.5 ml of type I collagen gel and the medium containing dexamethasone was changed on day 1 and day 4. At day 7, the PA activity of the medium was measured. Conditioned medium (10 ml) was added to 90 ml of assay solution (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 0.01% Tween 80, 40 mg/ml plasminogen (Chromogenix AB, Sweden) and 0.15 mg/ml H-D-Val-Leu-Lys-p-nitroanilide (Daiichi Kagaku, Tokyo, Japan)) in a 96-well microtiter plate and the plate was incubated at 37°C for 22 h. The absorbance of p-nitroaniline generated by plasmin-catalyzed cleavage of the substrate was measured with a microplate reader at 405 nm.
RESULTS
An angiogenesis model using an aortic fragment in collagen gel was first reported by Nicosia and Ottinetti. 18) They demonstrated that bFGF played an important role in capillary tube formation in their model. We investigated the involvement of other angiogenic factors, such as VEGF, VEGF receptor (Flk-1), MMP and PA, in the capillary-forming process in a similar model. In our experiment, migrating cells appeared after 3-5 d, followed by micro-vascular sprouts, and vascular growth continued for 1 to 2 weeks after the beginning of the experiment. The number of capillaries increased during day 3 to day 7 in the absence of exogenous factors (Fig. 1) . In order to analyze the expression levels of angiogenic factors, total RNA was prepared from an aortic fragment and capillary on day 0 (initial day) and day 7. The mRNAs of rat VEGF and rat VEGF receptor were analyzed by the RT-PCR technique and these molecules were found to be strongly induced on day 7, suggesting that they play a role in the angiogenic process. The level of rat b-actin mRNA was used as a control (Fig. 2) . PCR primers of rat VEGF, rat VEGF receptor and rat b-actin were designed from reported cDNA sequences. 19) MMP-2/proMMP-2 in the culture medium, assessed in terms of proteolytic activity in gelatin zymography, was also increased during capillary growth. On the other hand, MMP-9 was not detected at any time (Fig. 3) . Recently, it was reported that MMP-2 and -9 were produced in this model, and MMP inhibitor prevented the regression of capillaries at the late stage of angiogenesis. 20) In that study, MMP-9 was not detected in conditioned medium, but was found predominantly in the collagen gel, in accordance with our result. Furthermore, PA activity was detected on day 7 (see below) though not on day 4, suggesting that several types of proteases regulate the process of angiogenesis.
We investigated the activities of known angiogenesis inhibitors in the rat aorta model. The inhibitory activity was quantitatively measured by counting the capillary tubes around the aorta fragment on day 7 under a microscope. TNP-470, Marimastat, dexamethasone and SU5416 exhibited potent inhibition (Table 1 shows the IC 50 values). These results demonstrate that endogenous factors play an important role in angiogenesis. Interestingly, each inhibitor induced a distinct morphology in this model (Fig. 4) . TNP-470, a selective inhibitor of endothelial cell growth, 21) inhibited capillary formation without inhibiting the movement of migrating cells, which are mainly smooth muscle cells. Many migrating cells were observed even at a great distance from the aorta fragment (Fig. 4B) . Marimastat, an MMP inhibitor, 22) inhibited both cell migration and tube formation. Cells were observed only close to the aorta fragment, suggesting that cell migration is inhibited, in contrast to the case of TNP-470 (Fig. 4C) . Dexamethasone also inhibited both 448 Vol. 25, No. 4 Total RNA of one piece of rat aorta fragment (2 mmϫ2 mm) was isolated at day 0 (initial day) and day 7. Without RNA quantitation, one-fifth of total RNA solution was subjected to RT-PCR. Arrows indicate amplified DNA fragments on 1% agarose gel electrophoresis. Rat b-actin mRNA is used as an internal marker. cell migration and tube formation, but the cellular morphology was different from those in the cases of TNP-470 and Marimastat, suggesting that a distinct mechanism is involved. Large and short capillary-like structures were observed close to the aorta fragment (Fig. 4D) . But, at a higher concentration (25 nM), the morphology was similar to that in the case of Marimastat (data not shown). Since dexamethasone reportedly inhibits the production of PA 23) and MMP, 24) we checked the inhibitory activity of dexamethasone on PA production in our system. As shown in Fig. 5 , dexamethasone inhibited PA production in the rat aorta model in a dosedependent manner. Although dexamethasone exerts many biological activities through the steroid hormone receptor, PA appears to be a target molecule for anti-angiogenic activity. SU5416, a VEGF receptor kinase inhibitor, 25) showed a different mode of action from the other inhibitors. As mentioned above, the aortic fragment endogenously produced bFGF and this was involved in the initial induction of angiogenesis. However, the result obtained with SU5416 suggests that VEGF plays a more important role than bFGF in capillary formation in this model. A smaller number and a more immature state of tubes were observed. Fewer migrating cells may result from inhibition of the smooth muscle cell PDGF receptor, which is also inhibited by SU5416. These results suggest that the rat aorta model is able to categorize angiogenesis inhibitors on the basis of their mechanism, and it should be useful for studies of molecular mechanisms involved in the process of angiogenesis. Recently, we identified a class of angiogenesis inhibitors, luminacins, present in Streptomyces. 16) Luminacins are structurally novel natural products, and so far, 14 derivatives have been identified. 26) Luminacin C 2 , one of the bio-active derivatives, showed an IC 50 value of 50 ng/ml in the rat aorta model (Figs. 6, 7) , and exhibited a characteristic mode of action. The cells around the aorta fragment formed sheet-like structure at 0.03 mg/ml and higher (Fig. 6) , and single migrating cells were disappeared at 0.3 mg/ml. The cells in the sheetlike structure seemed to be tightly connected and formed a large capillary. This morphological change was observed at day 3 after the start of the experiment (data not shown). The target molecule of luminacins is unknown, but the unique morphology in this model suggests that luminacin acts on a novel molecule involved in the early stage of angiogenesis. 
DISCUSSION
Several in vitro angiogenesis models have been reported. Assays of cell proliferation, cell migration and tube formation are usually carried out by using isolated endothelial cells. 27) However, these models can not study the sequence of processes involved in angiogenesis, or the interactions among angiogenic factors. In the rat aorta model, we clarified that endogenous VEGF, VEGF receptor, MMP-2/proMMP-2 and PA were up-regulated. Villaschi and Nicosia reported that bFGF was initially released from the aorta fragment and disappeared during culture. 14) Both VEGF and bFGF are important growth factors for endothelial cells, but the previous findings 14) and our results indicate that the roles of these factors in angiogenesis are different; bFGF seems to be released at an early stage as a result of tissue injury, while VEGF is up-regulated in endothelial cells and mesenchymal cells in response to angiogenic stimuli such as hypoxia 28) and/or bFGF. 29) Proteolytic enzymes are another important factor in the angiogenic process. MMPs degrade the components of ECM and PA activates proteolytic enzymes, such as plasmin, which are necessary for cell migration at the early stage of angiogenesis. We investigated the morphological change induced by various protease inhibitors. Marimastat binds to the catalytic site and inhibits the proteolytic activity of MMPs. Dexamethasone has been reported to act as an angiogenesis inhibitor through the suppression of PA activity. 30) In the rat aorta model, both inhibitors inhibited capillary formation and cell migration. However, the morphological changes induced were different (Fig. 5) . Marimastat caused migrating cells to remain close to the aorta fragment and to remain separate, whereas dexamethasone inhibited migration by single cells. Recently, it was reported that MMP inhibitors stabilize the microvessels and prevent vascular regression at the late stage of angiogenesis in the aorta model. 20) TNP-470 inhibits the proliferation of endothelial cells through inhibition of methionine aminopeptidase 2. 31) On the other hand, SU5416 inhibits endothelial cell growth through blocking the VEGF signal in endothelial cells. In the rat aorta model, these inhibitors result in different morphologies, suggesting that this model is affected by various growth signals. SU5416 inhibited the migration of smooth muscle cells, as well as endothelial cells, suggesting that SU5416 inhibited not only VEGF receptor kinase on endothelial cells, but also PDGF receptor kinase on smooth muscle cells, in agreement with the suggestion that this compound inhibits both kinase activities.
25) It appears that morphological observation in the rat aorta model may allow us to predict the mechanism of action of inhibitors.
Luminacins were demonstrated to exhibit anti-angiogenic activity in the rat aorta model, and induced unique morphology in endothelial cells of the aorta. Luminacin C 2 inhibited cell scattering and the cells formed a sheet-like structure around the aortic fragment, suggesting that luminacin C 2 modulates cell-cell and/or cell-ECM adhesion. Experiments using monoclonal antibody demonstrated that adhesion molecules such as cadherin 5, 32) PECAM and integrins play roles in angiogenesis. However, little is known about the signals for regulation of adhesion molecules during angiogenesis. Luminacins may be useful as tools to investigate the regulation of adhesion molecules. Furthermore, collagen fragments such as endostatin, 33) tamustatin 34) and arrestin, 35) which bind to integrins, inhibit angiogenesis in vitro and in vivo. Endostatin, a fragment of collagen XVIII, showed potent effects in tumor models 36) and is under clinical study. These results suggest that the signals regulating adhesion molecules are interesting candidates as targets for the inhibition of tumor angiogenesis. Luminacins may modulate adhesion molecules through a novel mechanism, though further study is needed to confirm this.
Lastly, our results in the rat aorta model demonstrated that the capillary morphology in collagen gel changed depending upon the angiogenesis inhibitor employed. Some vessels are known to be functionally and structurally different, for example, brain capillaries, cardiac arteries and veins. Eph and ephrin are cell surface molecules guiding vessel development in the embryo to form the networks of arteries and veins, respectively. 37) Eph is expressed only on arteries and binds to ephrin on veins at the junction sites of arteries and veins. Experiments with eph and ephrin knockout mice supported the idea that eph and ephrin play important roles in angiogenesis. 38) Recently, it was reported that disruption of CXCR4, a chemokine receptor, results in lack of angiogenesis in the GI tract. 39) These results suggest that different molecules are required for angiogenesis in arteries, veins and the GI tract. Since rat vein fragments also formed capillaries, like rat aorta fragments, in collagen matrix culture (data not shown), it should be possible to study organ-specific angiogenesis by using fragments of blood vessels from lung, liver, brain and other organs.
